These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36724127)

  • 1. The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance.
    Gill RM; Allende D; Belt PH; Behling CA; Cummings OW; Guy CD; Carpenter D; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J; Van Natta ML; Wilson LA; Yamada G; Yeh M; Kleiner DE;
    Hepatol Commun; 2023 Feb; 7(2):e0033. PubMed ID: 36724127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    Brunt EM; Clouston AD; Goodman Z; Guy C; Kleiner DE; Lackner C; Tiniakos DG; Wee A; Yeh M; Leow WQ; Chng E; Ren Y; Boon Bee GG; Powell EE; Rinella M; Sanyal AJ; Neuschwander-Tetri B; Younossi Z; Charlton M; Ratziu V; Harrison SA; Tai D; Anstee QM
    J Hepatol; 2022 May; 76(5):1030-1041. PubMed ID: 35090960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Alexopoulos AS; Crowley MJ; Wang Y; Moylan CA; Guy CD; Henao R; Piercy DL; Seymour KA; Sudan R; Portenier DD; Diehl AM; Coviello AD; Abdelmalek MF
    Hepatology; 2021 Sep; 74(3):1220-1233. PubMed ID: 33724511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.
    Kamada Y; Akita M; Takeda Y; Yamada S; Fujii H; Sawai Y; Doi Y; Asazawa H; Nakayama K; Mizutani K; Fujii H; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    PLoS One; 2013; 8(6):e66328. PubMed ID: 23805214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies.
    Vanderbeck S; Bockhorst J; Kleiner D; Komorowski R; Chalasani N; Gawrieh S
    Hum Pathol; 2015 May; 46(5):767-75. PubMed ID: 25776030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acidophil bodies in nonalcoholic steatohepatitis.
    Yeh MM; Belt P; Brunt EM; Kowdley KV; Wilson LA; Ferrell L;
    Hum Pathol; 2016 Jun; 52():28-37. PubMed ID: 26980020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
    Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
    Leung HH; Puspanathan P; Chan AW; Nik Mustapha NR; Wong VW; Chan WK
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease.
    Sumida Y; Kanemasa K; Imai S; Mori K; Tanaka S; Shimokobe H; Kitamura Y; Fukumoto K; Kakutani A; Ohno T; Taketani H; Seko Y; Ishiba H; Hara T; Okajima A; Yamaguchi K; Moriguchi M; Mitsuyoshi H; Yasui K; Minami M; Itoh Y
    J Gastroenterol; 2015 Sep; 50(9):996-1004. PubMed ID: 25622927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.
    Patton HM; Yates K; Unalp-Arida A; Behling CA; Huang TT; Rosenthal P; Sanyal AJ; Schwimmer JB; Lavine JE
    Am J Gastroenterol; 2010 Sep; 105(9):2093-102. PubMed ID: 20372110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.